Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:39:12 EDT Mon 17 Aug 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:NAGE - NIAGEN BIOSCIENCE INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NAGE - Q0.43.02·3.320.13.020.415    10.52  2.8705:19:50Aug 1215 min RT 2¢

Recent Trades - All 5 today
Time ETExPriceChangeVolume
05:19:50Q3.02 200
05:19:41Q3.02 103
05:19:41Q3.030.011
05:19:34Q3.02 76
05:19:34Q3.030.011
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-08-12 08:32U:NAGENews ReleaseNiagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
2026-08-06 08:34U:NAGENews ReleaseNiagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
2026-08-04 16:02U:NAGENews ReleaseNiagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
2026-08-03 08:32U:NAGENews ReleaseNiagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
2026-07-28 08:32U:NAGENews ReleaseNiagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen(TM) (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
2026-07-27 08:32U:NAGENews ReleaseNiagen Bioscience to Present at Canaccord Genuity's 46th Annual Growth Conference
2026-07-21 08:32U:NAGENews ReleaseNiagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-13 08:32U:NAGENews ReleaseNiagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
2026-07-09 08:32U:NAGENews ReleaseNiagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
2026-07-08 08:32U:NAGENews ReleaseNiagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
2026-06-03 08:34U:NAGENews ReleaseNiagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
2026-06-02 08:32U:NAGENews ReleaseNiagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
2026-05-08 08:32U:NAGENews ReleaseNiagen Bioscience Announces Participation in Upcoming Investor Conferences
2026-05-06 16:02U:NAGENews ReleaseNiagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
2026-05-04 08:32U:NAGENews ReleaseNiagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
2026-04-28 08:32U:NAGENews ReleaseNiagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus(TM)
2026-04-22 08:32U:NAGENews ReleaseNiagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
2026-04-09 08:32U:NAGENews ReleaseNiagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen(TM)
2026-03-31 08:34U:NAGENews ReleaseNiagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
2026-03-19 08:32U:NAGENews ReleaseNiagen Bioscience Increases Share Repurchase Program to $20 Million